Selected article for: "antiviral treatment and drug combination"
Author: Çınar, Olgu Erkin; Sayınalp, Başak; Karakulak, Elifcan Aladağ; Karataş, Ayşe Avşar; Velet, Mustafa; İnkaya, Ahmet Çağkan; Ersoy Ortaç, Nazmiye Ebru; Öcal, Serpil; Aksu, Salih; Haznedaroğlu, İbrahim Celalettin; Sayınalp, Nilgün; Özcebe, Osman İlhami
Title: CONVALESCENT (IMMUNE) PLASMA TREATMENT IN A MYELODYSPLASTIC COVID-19 PATIENT WITH DISSEMINATED TUBERCULOSIS
  • Cord-id: vb88xlkm
  • Document date: 2020_5_29
    • ID: vb88xlkm
    Snippet: Abstract During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our exp
    Document: Abstract During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absolute lymphocyte count and macrophage activation: 1
    • absolute lymphocyte count and macrophage activation syndrome: 1
    • acute phase and administration schedule: 1
    • acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute phase and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute phase and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute phase reaction and lymphocyte count: 1
    • admission follow day and lymphocyte count: 1
    • lymphocyte count and macrophage activation: 1, 2, 3, 4, 5, 6
    • lymphocyte count and macrophage activation syndrome: 1, 2, 3, 4, 5